Program Description
Acute myeloid leukemia (AML)
is a rapidly progressing hematologic cancer that primarily affects older
adults. Approximately 50% of all patients with AML who achieve a first
remission will eventually relapse, and this rate is significantly higher in
older adults, as many are unable to tolerate the intensive chemotherapy and
consolidation therapy strategies. In recent years, the treatment landscape has
transitioned from "7+3" chemotherapy to a complex landscape of
molecularly targeted therapies, driven by molecular markers. The rapid approval
of targeted agents like FLT3, IDH1/2, and menin inhibitors has transformed AML
into a disease managed as much in the home as in the clinic. Yet, this approach
also has introduced significant challenges surrounding next-generation
sequencing results, adverse effect management, and appropriate medication use.
This webinar will explore the pathophysiology of AML, with a focus on how menin
inhibitors may be integrated into treatment regimens based on clinical trial
data in the frontline, relapsed/refractory, and post-transplant AML settings.
Expert faculty will discuss strategies to prevent and manage menin
inhibitor-related adverse effects. Best practices to support the
multidisciplinary team, share patient education, and implement community
oncology pharmacy logistics will also be presented.
Target audience: Oncology Pharmacist
Type of activity: Application
Release date: March
20, 2026
Expiration date: March
20, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.25 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the mechanism of action of menin inhibitors and the therapeutic rationale in acute myeloid leukemia (AML)
- Evaluate pivotal efficacy and safety data of commercially available and investigational menin inhibitors from clinical trials in AML
- Identify strategies for monitoring and managing adverse effects associated with commercially available and investigational menin inhibitors for the treatment of AML
- Develop pharmacist-led strategies to integrate menin inhibitors into AML care pathways, with attention to sequencing, adherence, and supportive care
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here